INEZOLID VS VANCOMYCIN IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS DUE TO PRESUMED OR PROVEN TO A GRAM POSITIVE GERM RESISTANT TO METICILLI

PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,0 个研究点目标入组 0 人开始时间: 2001年11月22日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•The subjects must be at least 18 years of age.
•At the time of enrollment, patients are expected to survive effective antibiotic therapy and appropriate supportive care during treatment and follow-up.
•Patients should be willing to complete all activities related to the study.
•Patients who, after controlling for their acute infection, can be discharged for outpatient therapy.
•Patients who have specific signs and symptoms of an active infection, as indicated below for the following clinical syndromes.

•Patients with infected devices, when these are not removed.
•Hypersensitivity to linezolid, vancomycin or to one of the excipients in any drug formulation.
•Simultaneous use of another medication in research.
•Patient with osteomyelitis, endocarditis, meningitis or septic arthritis.
•Necrotizing fasciitis, caseose gangrene.
•Medical conditions in which the inflammation is prominent for a prolonged period, even after bacterial eradication, for example: superinfected eczema or atopic dermatitis.
•Patients with uncomplicated skin infections and superficial dermal structures such as superficial cellulitis, impetigo, boil, or simple abscess that only requires surgical drainage at the time of enrollment.
•Patients with self-limited infections such as isolated folliculitis in another infection that has a high cure rate with surgical incision or furunculosis or carbunculosis, not associated with cellulitis, of at least 1cm radius.
•Patients likely to require long-term hospitalization because of concomitant morbidities (for example: patients likely to require a prolonged stay in the hospital with ventilator use, etc.) Hospitalization due to an underlying comorbidity, where their treatment probably requires more time than the treatment of acute infection.
•It is proven that the acute infection is not due to a gram-positive bacterial pathogen, or only due to a gram-negative pathogen.

发起方

PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,